RESEARCH

High prevalence of extensively drug resistant and extended spectrum beta lactamases (ESBLs) producing uropathogenic *Escherichia coli* isolated from Faisalabad, Pakistan

Beenish Ehsan[1] · Asma Haque[1] · Muhammad Qasim[1] · Aamir Ali[2] · Yasra Sarwar[2]

Abstract

Urinary tract infections (UTIs) are predominantly caused by uropathogenic *Escherichia coli* (*E. coli*). There is rapid increase in antimicrobial resistance in UTIs, also declared as a serious health threat by World Health Organization (WHO). Present study was designed to investigate the antimicrobial resistance status with specific focus on ESBLs and carbapenemases in local uropathogenic *E. coli* (UPEC) isolates. *E. coli* isolates were characterized from patients of all ages visiting diagnostic laboratories for urine examination. Demographic data was also recorded for each patient. Antibiograms were developed to observe antibiotic resistance in UPEC using Kirby Bauer disc diffusion technique. Double Disc Synergy test (DDST) was used for phenotypic ESBL test. ESBLs and carbapenemases genes were detected in UPEC using PCR. The PCR results were confirmed by sequencing. The UPEC isolates under study exhibited 78%, 77%, 74%, 72% and 55% resistance against cefotaxime, amoxicillin, erythromycin, ceftriaxone and cefixime, respectively. Resistance against colistin and meropenem was observed in 64% and 34% isolates, respectively. Phenotypic DDST identified 48% isolates as ESBLs producers. Genotypic characterization identified 70%, 74.4% and 49% prevalence of CTXM-1, TEM-1 and CTXM-15 genes respectively. One isolate was observed exhibiting co-existence of all ESBL genes. TEM-1 + CTXM-1 and TEM-1 + CTXM-1 + CTXM-15 + OXA-1 gene patterns were dominant among ESBLs. For carbapenem-resistance, 14% isolates indicated the presence of KPC whereas GES and VIM was detected in 7% and 3.4% isolates, respectively. In conclusion, our results present a high prevalence of extensively drug resistant UPEC isolates with a considerable percentage of ESBL producers. These findings propose the need of continuous surveillance for antimicrobial resistance and targeted antimicrobial therapy.

Keywords Extended spectrum beta lactamases · Extensively drug resistant · Uropathogenic · Carbapenemase

Introduction

Urinary tract infections (UTIs) are among the most prevalent infectious diseases reaching the overall incidence of 18/1000 in general population (Sohail et al. 2015). In

✉ Asma Haque
asma@gcuf.edu.pk

✉ Yasra Sarwar
yasrasarwar@yahoo.com

[1] Department of Bioinformatics and Biotechnology, Government College University Faisalabad (GCUF), Faisalabad, Pakistan

[2] Pakistan Institute of Engineering & Applied Sciences (PIEAS), National Institute for Biotechnology and Genetic Engineering College (NIBGE-C), Faisalabad & Islamabad, Pakistan

Pakistan, antibiotic-resistant UTI's are the most reported clinical infections and uropathogenic *Escherichia coli* (*E. coli*) is considered responsible for approximately 70–90% UTIs (Larramendy et al. 2020; Kahlmeter and Poulsen 2012; Tandogdu and Wagenlehner 2016; Foxman 2014). Upper UTI (pyelonephritis) is a major cause of hypertension, renal insufficiency and end-stage renal failure in children (Nader and Alejandro 2021). Early treatment of UTI with an effective antibiotic is essential for preventing long-term consequences. Treatment delay increases the risk of renal scarring and progressive kidney damage (Baziboroun et al. 2018; Terlizzi et al. 2017).

Urinary tract infections are mostly associated with increased resistance to antimicrobial agents. The emergence of multidrug resistance in UPEC may be attributed to frequent and injudicious use of antibiotics without culture sensitivity testing (Adamus-Białek et al. 2018). Additionally,

extended spectrum beta-lactamases (ESBLs) are the resistance mechanisms evolved by Gram-negative bacteria, causing burden on clinical therapeutics and resulting in higher morbidity with delayed treatment and isolates are increasing at exponential rate (Shilpakar et al. 2021). ESBLs are plasmid mediated beta-lactamase genes, capable of hydrolyzing 3rd and 4th generation cephalosporins, and aztreonam (Yengui et al. 2022; Jalal et al. 2023). ESBLs are designated main drug-resistant pathogens and major variations have been detected globally in ESBL-producing isolates (Shilpakar et al. 2021; Doi et al. 2017). World Health Organization (WHO) designated ESBL-producing enteric bacteria/enterobacteriaceae as the supreme critical group for research (Larramendy et al. 2020). Plasmids harbor the genes for ESBLs that are extremely mobile and might contain genes conferring resistance to other antimicrobial groups like quinolones and aminoglycosides (Ugbo et al. 2020). SHV, TEM and CTX-M are the most common families among ESBLs (Mahamat et al. 2019; Ur Rahman et al. 2018**).**

In Enterobacteriaceae, increasing trend of carbapenem resistance has been reported globally from health care associated and community settings (Tilahun et al. 2021; Macareño-Castro et al. 2022). The rising incidence of carbapenem resistance is alarming. Antibiotic resistance is disseminated by different methods like ESBLs and carbapenemases, AmpC β-lactamases and porin loss. Increasing incidence of antibiotic resistance is associated with few treatment options (Tilahun et al. 2021).

Colistin is utilized as a last-resort antibiotic for the therapy of Enterobacteriaceae that are characterized as producers of carbapenemases and ESBLs. Colistin-resistant *E. coli* strains have become prevalent due to colistin use in farm animals (Macareño-Castro et al. 2022; Dhaouadi et al. 2020).

There are limited treatment strategies for the management of multidrug-resistant (MDR) strains and the diversity of virulence factors in *E. coli* (Liu et al. 2016). It is, therefore, necessary to investigate the drug resistance profiles of UPEC strains. There are very few studies on UPEC isolates from Faisalabad region (Haghighatpanah and Mojtahedi 2019; Bashir et al. 2012, 2011). There is no latest data available on UPEC locally in community settings regarding antibiotic resistance patterns. The study will provide information about circulating resistance genes in the community.

Material and methods

Study design

A total of 540 urine samples were collected from September 2018 to February 2020 from four clinical laboratories (Millat Laboratory, National Laboratory, Khidmat-E-Khalaq Laboratory and Meezan Laboratory) in Faisalabad city, Pakistan.

Sterile screw-capped, wide cover containers were used to collect urine. One isolate was collected from each patient, avoiding sample repetition from the same patient. *Inclusion criteria* were (i) Outpatients, (ii) all age groups (iii) both genders and (iv) Positive urine culture with presumptive *E. coli* characterization. *Exclusion criteria* were (i) Inpatients and uropathogens other than *E. coli.*

Isolation and identification of UPEC from clinical samples

Urine samples were initially streaked on MacConkey agar (Acumedia, Michigan, US) and Cysteine Lactose Electrolyte Deficient (C.L.E.D.) agar (Hi Media laboratory Pvt Ltd, Mumbai, India) (MacConkey agar served as a selective as well as a differential culture medium. MacConkey agar was used for the isolation of Gram-negative uropathogens while C.L.E.D. agar was used for the differentiation of uropathogens based on color morphology. All media were prepared according to the manufacturer's instructions. Urine samples were streaked on media using sterile cotton swabs. Media plates were incubated at 37 ℃ overnight. Next day, plates were observed for growth. The colony of interest was picked from media containing selected pathogen using a sterile loop and mixed in 3% H_2O_2 on the slide for catalase test. Air bubbles and water were observed on a slide for a positive result (Habeeb et al. 2013). Triple sugar iron test is used for the characterization of various pathogens. This test is based on the pathogen's ability for fermentation of sugars, H_2S production and gas production. For TSI agar (BIOCHEM chemopharma, France), colony inoculation was performed by stabbing through the center of the medium to the bottom of the test tube and then streaking was also performed on the slant. Test tubes were incubated at 37 ℃ for 18 h.

Molecular confirmation of UPEC

DNA was extracted from characterized UPEC isolates by using the conventional phenol–chloroform method (Choudhary et al. 2022). Briefly, 1.5 ml of bacterial culture was centrifuged at 10,000 rpm for 10 min. The pellet was washed in 1 ml of 10 mM Tris–HCl [pH 8.0] and re-suspended in 10% SDS followed by heating at 65 °C for 1–2 h. This bacterial suspension was mixed vigorously with chloroform:isoamyl alcohol (24:1), centrifuged at 10,000 rpm for 5 min. The supernatant containing DNA was separated. This step was repeated three times. Finally, sodium acetate (3 M; pH 4.8) and chilled isopropanol was added, mixed and stored at -20 °C overnight. This DNA preparation was centrifuged at 10,000 rpm for 10 min and supernatant was discarded. The DNA pellet was treated with 70% ethanol, the pellet was air dried and suspended in 10 mM Tris–HCl [pH 8.0]. Molecular identification was carried out using Polymerase

Chain Reaction (PCR) by targeting *uidA* gene encoding β-glucuronidase (Table 2). The identified UPEC isolates were stored at − 20 °C as 30% glycerol stocks.

Table 1 Antibiotics used in this study

Sr. No	Group of antibiotic	Drugs
1	Carbapenems	Meropenem(10 μg)
2	Cephalosporins	Sulbactam/ cefoperazone(105 μg)
		Cefixime(5 μg)
		Ceftriaxone(30 μg)
		Cefotaxime(30 μg)
		Ceftazidime(30 μg)
3	Quinolones and fluoroquinolones	Ofloxacin(5 μg)
		Moxifloxacin(5 μg)
		Pipemidic Acid(20 μg)
4	Aminoglycosides	Gentamycin(30 μg)
		Fosfomycin(50 μg)
		Tobramycin(10 μg)
5	Penicillins	Ampicillin/sulbactam(20 μg)
		Amoxycillin(10 μg)
		Piperacillin/ Tazobactam(110 μg)
6	Nitorfuran	Nitrofurantoin(300 μg)
7	Sulfonamides	Trimethoprim(5 μg)
8	Monobactams	Aztreonam(30 μg)
9	Macrolide	Erythromycin(30 μg)
10	Polymyxin	Colistin sulphate (10 μg)

Assessment of antibiotic resistance

Antibiograms of confirmed UPEC isolates were examined y following the Kirby-Bauer method (Sambrook and Fritsch 1989). Glycerol stocks were revived for obtaining fresh growth. Each isolate was inoculated in Tryptic Soy Broth at 37 °C. When turbidity was assessed according to 0.5 MacFarland standard, sterile cotton swabs were used for making a lawn culture on Mueller–Hinton Agar (MHA). Antibiotic discs were placed on the surface of inoculated MHA using sterile forceps. The plates were checked for zones of inhibition after overnight incubation at 37 °C. Antibiotic resistance was examined by using guidelines provided by the Clinical and Laboratory Standards Institute (Bauer et al. 1996; CLSI 2016). Colistin interpretation was performed according to criteria described by Gales et al. (CLSI 2013). Belonging to 10 groups, 20 antibiotics (OXOID, UK) were used in this study (Table 1). UPEC isolates were categorized as extensively drug resistant (XDR) and MDR (CLSI 2016).

Phenotypic Assay for ESBL production

Each isolate was processed through Double Disc Synergy test (DDST) (Gales et al. 2001; Magiorakos et al. 2012). DDST was performed using five antibiotic discs (OXOID); amoxicillin-clavulanic acid (AMC), aztreonam (ATM), ceftriaxone (CRO), ceftazidime (CAZ) and cefotaxime (CTX).

Table 2 Primers used in this study

Sr. No	Gene	Primer sequence (5′–3′)	Anneal. temperature	Product size (bp)	References
1-	*uidA*	F:ATCACCGTGGTGACGCATGTCGC R:CACCACGATGCCATGTTCATCTGC	50	486	Bashir et al. (2012)
2-	*bla SHV-1*	F: GGCCGCGTAGGCATGATAGA R: CCCGGCGATTTGCTGATTTC	60	714	Wajid et al. (2019)
3-	*bla TEM-1*	F: CAGCGGTAAGATCCT TGAGA R: ACTCGCCGTCGTGTAGATAA	55	643	Wajid et al. (2019)
4-	*bla CTX-M1*	F: AACCGTCACGCTGTTGTTAG R: TTGAGGCTGGGTGAAGTAAG	55	766	Wajid et al. (2019)
5-	*bla CTX-M15*	F: CAATGTGCAGCACCAGTAA R: CGCAATATCATTGGTGGTG	58	540	Wajid et al. (2019)
6-	*bla CMY-2*	F: TGGCCGTTGCCGTTATCTAC R: CCCGTTTTATGCACCCATGA	55	870	Wajid et al. (2019)
7-	*bla SHV-12*	F:GGTTATTCTTATTTGTCGCTTCTT R:TACGTTACGCCACCTGGCTA	55	1233	Wajid et al. (2019)
8-	*OXA-1*	F: AATGGCACCAGATTCAACTT R: CTTGGCTTTTATGCTTGATG	55	640	Li & Wang (2017)
9-	*bla KPC*	F:CGTCTAGTTCTGCTGTCTTG R:CTTGTCATCCTTGTTAGGCG	55	538	Farajzadeh-Sheikh et al. (2020)
10-	*bla VIM*	F:GTTTGGTCGCATATCGCAAC R:AATGCGCAGCACCAGGATAG	60	389	Awan et al. (2021)
11	*bla GES*	F: GTTTTGCAATGTGCTCAACG R: TGCCATAGCAATAGGCGTAG	56.65	371	Poirel et al. (2011)

AMC (20/ 10 µg) was placed at the centre of Mueller–Hinton agar plate containing inoculum of desired isolate. Other discs were placed 15 mm apart from AMC. Plate-containing discs was placed inverted in incubator at 37 ℃ overnight. The plate was observed for extension of inhibitory zone from 3rd generation cephalosporins toward AMC forming a characteristic shape denoted as "key hole".

Molecular detection of ESBLs and carbapenemases

Molecular methods are best described for having specificity and sensitivity for the detection of resistance genes while consuming minimum time (Aruhomukama 2020). Molecular detection was performed by PCR using gene specific-primers (e-oligo, USA) (Table 2). PCR conditions were same for each primer set except annealing temperature. For ESBLs, PCR conditions were 94 °C for 5 min (initial denaturation) followed by 30 cycles of 94 °C for 30 s (denaturation), annealing (primer specific) for 30 s and 72 °C for 30 s (extension) and 72 °C for 5 min (final Extension). For carbapenems, PCR conditions were 94 °C for 5 min (initial denaturation) followed by 30 cycles of 94 °C for 30 s (denaturation), annealing (primer specific) for 40 s and 72 °C for 50 s (Extension) and 72 °C for 5 min (final extension).

PCR products were run through 1.5% (w/v) agarose gel in Tris–Borate- Ethylene diamine tetra acetic acid (TBE) buffer in an electrophoresis chamber (Thermo ELECTRON CORPORATION, USA) and detected using ultraviolet transilluminator. Voltage was adjusted to 120 V and PCR products were run for 45 min through agarose gel.

Sequencing of PCR Products

The PCR products were sequenced to check the presence of different ESBL genes in these isolates.

Statistical Analysis

The data was analyzed using GraphPad Prism 8.4.2, the Fisher's exact test (2-tailed) value was found for the comparison of antimicrobial resistance profiles of ESBL producers and non-producer to check any significant differences between two batches of the collected isolates. P-value was calculated through Fisher's Exact Test and was considered significant if less than 0.05.

Results

Phenotypic Identification of UPEC

Lactose fermentation and pink colonies were observed on MacConkey agar plates. On C.L.E.D. agar, bright pink colonies (with pink halo) were observed for UPEC among other uropathogens. Purified colonies were further confirmed by stabbing in TSI agar. Isolates having characteristics of yellow slant, yellow butt, gas positive(cracks/bubbles indication in agar) and H_2S negative, were processed further for molecular characterization.

Phenotypic and genotypic confirmation of UPEC

There was no polymicrobial culture in urine samples. Out of 540 samples, 500 samples showed positive growth on culture media. Out of 500, 170 (34%) proved to be *E. coli* by phenotypic assays. Out of these presumptive 170 *E. coli* isolates, 89 (52.4%) exhibited the presence of *uidA* gene. There might be variations in *uidA* gene due to which 89 samples indicated presence of this gene (Clinical and Laboratory Standards Institute 2010).

Demographic Data

Out of 89, female population was 70 (79%) whereas male population was 19 (21%). Age data indicated that No. of < 18 years patients were 5 (6%); 18–60 years were 76 (85%) and > 60 years were 8 (9%). Among ESBL producers; females were 25 (58%) whereas males were 18 (42%). Age-wise distribution among these patients was < 18 years were 3 (7%), 18–60 years were 38 (88%) and > 60 years were 2 (5%). Among non-ESBL producers; females were 45 (98%) while only one was male (2%). Age-wise distribution among these patients was < 18 years were 2 (4%), 18–60 years were 38 (83%) and > 60 years were 6 (13%).

Phenotypic confirmation of ESBL production and antibiotic resistance

XDR UPEC isolates were 63 (71%) Out of 89, 43 (48%) isolates exhibited the presence of ESBLs by DDST. UPEC isolates indicated 78%, 77%, 74%, 72%, 59% and 55% resistance against cefotaxime, amoxicillin, erythromycin, ceftriaxone, ceftazidime and cefexime, respectively. For colistin; 50% isolates indicated intermediate zones and 14% showed resistance. Meropenem resistance was observed 22% UPEC isolates. Susceptible and intermediate UPEC isolates were 66.5% and 11.5%, respectively. The intermediately resistant isolates were considered resistant during statistical and data analysis (Fig. 1, Fig. 3, Table 3).

Among ESBL-producers, these isolates possessed 100%, 93%, 88%, 79% and 79% resistance against erythromycin, amoxycillin, cefotaxime, ceftriaxone and cefixime, respectively. For colistin; 30 (70%) isolates exhibited intermediate zones and 1(3%) showed resistance. For meropenem; 15% showed resistance, 10% intermediate zones and 75% showed sensitivity to meropenem.

Fig. 1 Graphical presentation of antibiogram of UPEC in the study

Gene Detection according to Ambler Classification

Ambler classification is based on the discrimination of resistance pattern induced by these enzymes and in most of the cases Class A and Class D is present (Aruhomukama 2020). In our study, isolates indicated the presence of Class A genes (84% ESBLs + 19% Carbapenemases) (Fig. 2).

Occurrence of ESBL genes

All isolates indicated the presence of gene(s) except three isolates (Table 4). One isolate indicated the presence of all the tested genes.TEM-1, CTXM-1 and CTXM-15 were present in 74.4%, 70% and 49%, respectively. SHV-1 and OXA-1 were present in 21% and 16.2% isolates respectively. SHV-12 was present in 14% isolates and CMY-2 was present in 9.3% isolates (Table 4). These genes were also co-existed in different patterns in ESBL-positive isolates. TEM-1 + CTXM-1 and TEM-1 + CTXM-1 + CTXM-15 + OXA-1 patterns indicated high prevalence followed by TEM-1 + CTXM-1 + CTXM-15 and TEM-1 + CTXM-1 + CTXM-15 + SHV-1 + OXA-1 gene patterns (Table 5).

Molecular detection of carbapenem-resistance

Klebsiella pneumoniae carbapenemase (KPC), Verona integron-encoded MBL (VIM) and Guiana extended spectrum (GES) carbapenems (Noster et al. 2021) were detected in this study. Two (7%) isolates indicated the presence of GES and VIM was detected in one (3.4%) isolate. KPC was detected in four (14%) isolates. Co-existence was not observed for carbapenem resistance genes Figs. 4 and 5.

Sequenced PCR Products

Sequences were aligned with protein databases using blastx on NCBI website (https://blast.ncbi.nlm.nih.gov/Blast.cgi). Sequences represented significant alignment with their related proteins (WP_240093217.1, AKE33354.1, ACG58887.1, WP_063859857.1, NPI00138.1, and AFR79065.1). Sequences were 99%, 100%, 83%, 96%, 99%, and 97% identical respectively.

**Fig. 2** Distribution of ESBLs and carbapenem-resistance genes on the basis of Ambler classification

Table 3 Comparative analysis of AMR profile of ESBL producers and non-producers

Antimicrobial drugs	Non-ESBL producing UPEC isolates (n=46)		ESBL producing UPEC isolates (n=43)		*p value*
	Resistant	Susceptible	Resistant	Susceptible	
Meropenem	29 (63%)	17 (37%)	11 (26%)	32 (74%)	0.0006***
Fosfomycin	0 (0%)	46 (100%)	1 (2%)	42 (98%)	0.4831
Tobramycin	17 (37%)	29 (63%)	13 (30%)	30 (70%)	0.6540
Gentamycin	7 (15%)	39 (85%)	9 (21%)	34 (79%)	0.5845
Erythromycin	45 (98%)	1 (2%)	43 (100%)	0	1.0000
Pipemidic Acid	17 (37%)	29 (63%)	23 (54%)	20 (46%)	0.5845
Moxifloxacin	25 (54%)	21 (46%)	22 (51%)	21 (49%)	0.8332
Ofloxacin	25 (54%)	21 (46%)	16 (37%)	27 (63%)	0.1372
Nitrofurantoin	7 (15%)	39 (85%)	1 (2%)	42 (98%)	0.0593
Aztreonam	27 (59%)	19 (41%)	34 (79%)	9 (21%)	0.0435*
Trimethoprim	33 (72%)	13 (28%)	28 (65%)	15 (35%)	0.6483
Ceftazidime	28 (61%)	18 (39%)	32 (74%)	11 (26%)	0.1847
Ceftriaxone	33 (72%)	13 (28%)	34 (79%)	9 (21%)	0.4689
Cefexime	34 (74%)	12 (26%)	34 (79%)	9 (21%)	0.6237
Cefotaxime	35 (76%)	11 (24%)	38 (88%)	5 (12%)	0.1709
Sulbactam/ cefoperazone	7 (15%)	39 (85%)	9 (21%)	34 (79%)	0.5845
Piperacillin/ Tazobactam	9 (20%)	37 (80%)	6 (13%)	37 (87%)	0.5763
Amoxycillin	44 (96%)	2 (4%)	40 (93%)	3 (7%)	0.6698
Ampicillin/ sulbactam	11 (24%)	35 (76%)	10 (23%)	33 (77%)	1.0000
Amoxicillin / Clavulanic acid	9 (20%)	37 (80%)	7 (17%)	36 (83%)	0.7856
Colistin sulphate	36 (78%)	10 (22%)	31 (72%)	12 (28%)	0.6242

***Indicates extremely statistically significant

*Designates statistically significant

Table 4 Occurrence of ESBL genes

ESBL genes	Isolate no. (%)
CTXM-1	30 (70%)
TEM-1	32 (74.4%)
CTXM-15	21 (49%)
CMY-2	4 (9.3%)
SHV-12	6 (14%)
SHV-1	9 (21%)
OXA-1	7 (16.2%)

Interpretation of Statistical Analysis

The comparative antimicrobial resistance between ESBL producers and ESBL non producers was found extremely significant by statistical analysis for aztreonam, amoxicillin, erythromycin, cefixime and trimethoprim. Ceftazidime indicated very significant association. Nitrofurantoin, ofloxacin and cefotaxime indicated statistical significance.

Discussion

Urinary tract infection has become a significant problem due to emergence of MDR pathogens in human population (Godambe et al. 2017). *E. coli* is a major cause of infections in newborns and all age groups in both hospital and community settings (Aurilio et al. 2022). Among UPEC isolates, high resistance rates were observed in amoxicillin, cefotaxime, ceftriaxone, ceftazidime and cefixime indicating 77%, 78%, 72%, 59% and 55% resistant isolates respectively in this study. Our study is in accordance with the reports from different centers indicating resistance against 3rd generation cephalosporins and penicillins in Pakistan (Coura et al. 2021; Wu et al. 2021; Ahmed et al. 2022). ESBL producing UPEC bring about resistance against broad-spectrum antibiotics like 3rd generation cephalosporins due to the empiric use of these antibiotics for UTIs (Akhtar et al. 2021). In the present study, 64% resistance was observed in for colistin sulphate. Colistin sulphate, fosfomycin, nitrofurantoin, polymyxin B, and chloramphenicol proved promising for Paediatric patients of UTIs at the Institute of Child Health, Lahore, Pakistan (Nasir, et al. 2021). Another study from Children Hospital Lahore, indicated high susceptibilities

Table 5 Co-existence of ESBL genes

Gene Pattern	Isolate no. (%)
TEM-1+CTXM-1	5 (12%)
TEM-1+CTXM-1+CTXM-15	4 (9.3%)
TEM-1+CTXM-15	2 (5%)
TEM-1+CTXM-1+CTXM-15+CMY-2+SHV-12+SHV-1	2 (5%)
TEM-1+CTXM-1+CTXM-15+CMY-2	1 (2.3%)
TEM-1+CTXM-1+SHV-12	1 (2.3%)
TEM-1+CTXM-1+SHV-1	2 (5%)
TEM-1+CTXM-1+CTXM-15+SHV-1	2 (5%)
TEM-1+CTXM-1+CTXM-15+OXA-1	5 (12%)
TEM-1+CTXM-1+CTXM-15+SHV-1+OXA-1	3 (7%)
TEM-1+CTXM-1+SHV-1+OXA-1	1 (2.3%)
TEM-1+CTXM-1+OXA-1	2 (5%)
TEM-1+CTXM-1+CTXM-15+SHV-1+OXA-1+VIM	1 (2.3%)

for colistin (84.8%), nitrofurantoin (64.7%) and meropenem (54%) (White 2021). Uropathogenic gram negative bacteria were 22.8% that indicated resistance against colistin from patients at Peshawar, Pakistan (Iqbal et al. 2021). In this study, significant ESBL prevalence (48%) was found by DDST Naeem et al. reported 57.89% ESBL-positive *E. coli* isolates recovered from tertiary care centres of Peshawar and Islamabad (Mir et al. 2022). From Karachi, Nasir et al. reported 66.2% ESBL-producing *E. coli* isolates retrieved from urology department of Jinnah postgraduate medical center (Arif et al. 2022). Khan and Bari reported 92% ESBL-positive *E. coli* from urine samples at Qazi Hussain Ahmed Medical Complex Nowshera (Naeem et al. 2021). A study was conducted by Samin et al. at Diabetes Hospital Peshawar and Nishter Hospital Multan, ESBL-positive *E. coli* isolates were recovered from 81.4% subjects (Nasir et al. 2021)..Percentages of TEM-1 and CTXM-1 were 74.4% and 70% in this study. CTX-M enzymes are the most prevalent ESBLs and declared pandemic. TEM enzymes have been studied well and contribute 90% resistance in *E.*

coli reviewed by Hussain et al. Khan and Bari 2021). TEM gene has also been found mainly (66.6%) in hospital aerosols from Tai'an City, China (Samin et al. 2021). There is significant proportion (49%) of isolates containing CTXM-15 in present investigation. Latest research from different countries around the globe also indicated a high prevalence of CTXM-15 (Hussain et al. 2021; Wu et al. 2020; Hassuna et al. 2020; Legese et al. 2022; Carvalho et al. 2021). High prevalence of CTXM-15 is responsible for clonal dissemination of ST-131 armed with ESBL genes and virulence factors. ST-131 also dominantly colonizes human gut(Surgers et al. 2019) CTXM-15 gene was also found significantly in companion animals in Italy, Germany and Europe Companion animals have become reservoires of CTXM-15 gene in Italy, Germany and Europe. ST131 clone of UPEC remained responsible for this gene most of the time. ST131 is responsible for MDR infections globally (Hassuna et al. 2020). Others also investigated ST131 and found predominance of CTXM-15 (Surgers et al. 2019; Mazumder et al. 2020). Co-existence of TEM-1 and CTXM-1 was present in 12%


Fig. 3 Phenotypic detection of ESBLs by DDST. Figure parts **A** and **B** indicate synergy between AMC and CTX, CAZ, ATM and CRO. Figure part **C** indicates synergy between AMC and CRO, CAZ and ATM

Fig. 4 Genotypic detection of ESBL genes (TEM-1, CTXM-15, CTXM-1, OXA-1) by PCR Lane M indicates sizes (in base pairs) of 3000, 2000, 1500, 1200, 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100 (Cat no. SM0323, Thermo Fisher Scientific, USA) Part **A** (Lane 1&2) represents the amplification of TEM-1 gene (643 bp) Part **B** (Lane 1&2) represents the amplification of CTXM-15 gene (540 bp) Part **C** (Lane1, 2 and 3) represents the amplification of CTXM-1 gene (766 bp) Part **D** (Lane 1 and 2) represents the amplification of OXA-1 (640 bp)

Fig. 5 Genotypic detection of ESBL genes (SHV-1, SHV-12, CMY-2, *uidA*) by PCR Lane M indicates sizes (in base pairs) of 3000, 2000, 1500, 1200, 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100 (Cat no. SM0323, Thermo Fisher Scientific, USA) Part **E** (Lane 1) represents the amplification of SHV-1 (714 bp) Part **F** (Lane 1, 2 and 3) represents the amplification of SHV-12 (1233 bp) Part **G** (Lane 1, 2 and 3) represents the amplification of CMY-2 (870 bp) Part **H** (Lane 1 and 2) represents the amplification of *uidA* (486 bp)

isolates in our case. A meta-analysis from Pakistan indicated abundance of CTXM-1 and co-existence of this gene TEM (Abdelrahim et al. 2021). In our study co-existence of CTXM-15 with TEM-1 and CTXM-1 was 9.3%, benefitting bacteria to escape pressure of multiple antibiotic treatments thus worsening the situation. In Philippines, Samples from pig farms indicated 4.17% co-existence of these genes (Alqasim et al. 2020).

Antibiotic usage in poultry is transferring ESBLs to humans at community level (Bilal et al. 2021; Gundran et al. 2019).

In our study SHV-1 was found in few isolates (21%) and SHV-12 was also found in low percentage (14%). The prevalence was in accordance with different studies performed around the globe. Pandit et al. detected 4.8% SHV in MDR UPEC isolates (Falgenhauer et al. 2019) In Upper Egypt, 59.7% isolates indicated ESBL-production from 62% MDR UPEC. SHV was co-existed with CTX-M in 10% isolates and co-existence of SHV with TEM was present in 6.25% isolates (Hussain et al. 2021). Nwafia et al. detected SHV in 2.86% *E. coli* isolates recovered from both community and hospital. SHV was also coexisted with CTX-M in 20% isolates and in TEM/CTX-M in 14.29% isolates (Kim et al. 2021).SHV was detected in high prevalence (39.44%) among drug users (Nahar et al. 2022). SHV enzymes are detected frequently in *Klebsiella pneumoniae* outbreaks than *E. coli* (Khan and Bari 2021). In this study, CMY-2 gene was present in 9.3% isolates ESBL genes are not unique for

UPEC and these genes are found in *E. coli* derived from different sources. CMY type is predominantly detected type of plasmid- mediated AmpC and 64 plasmid- mediated variants exist of CMY type. Multidrug resistance emerges due to plasmid-mediated AmpC β-lactamase production(Pandit et al. 2020).CMY-2 (n = 2) wasdetected in *Enterobacteriaceae* isolated from sepsis patients(Wu et al. 2020). CMY-2 was detected in 3.7% carbapenem resistant *E. coli* isolates recovered from tertiary-care center in Lebanon(Nwafia et al. 2019). In Mexico, 4.5% isolates indicated presence of CMY-variants in paediatric patients (Barani et al. 2021). Poultry meat has been declared a main source of ESBL/AmpC-producing *E. coli* and *K. pneumonia* (Muriuki et al. 2022) ESBL/AmpC-producing *E. coli* recovered from calves were at high frequency as compared to cows/ manure pits at farms in Quebec, Canada (Dagher et al. 2018).

Prevalence of OXA-1 was 16.2% in this study. The result is in accordance with reports on extraintestinal *E. coli* (Carvalho et al. 2021) and female patients with UTI episode (Merida-Vieyra et al. 2020). OXA-1 was also detected in fecal samples of healthy individualsin India (Kurittu et al. 2021) and USA (Massé et al. 2021). It is the indication of *E. coli* being a reservoir of antimicrobial resistance genes. There are reports about co-existence of OXA-1 gene with NDM-5 and CTXM-variants /only with NDM-5 (Zeng et al. 2021; Chandran et al. 2017; Rubin et al. 2020). In this study, OXA-1 co-existed with different genes. TEM-1+CTXM-1+CTXM-15+OXA-1 pattern was present in 12% isolates. Virulent MDR *E. coli* isolates that produce ESBLs, are the main reason for UTI severity and it may lead to acute kidney injury, considered an important risk factor for diabetic patients (Nasir et al. 2021; Hao et al. 2022). Three isolates did not indicate presence of any gene which might be due to the production of different enzymes.

In our study, 34% UPEC isolates indicated resistance against meropenem and presence of carbapenemase genes is another alarming finding. KPC gene was detected in 14% isolates. From Pakistan, recent reports indicated the presence of NDM in pediatric patients (Sun et al. 2018; Corbellini et al. 2022) and along with other carbapenemase genes from hospital-settings [81 whereas NDM was not detected in our study. In Islamabad, occurrence of carbapenem-resistances genes has been detected along with ESBLs in sewage indicating circulation of genes in community (Naziri et al. 2020). TEM-1+CTXM-1+CTXM-15+SHV-1+OXA-1+VIM pattern was observed in one isolate in our study and only that isolate indicated presence of VIM gene. GES was present in 7% isolates in this study. Systematic review analysis indicated UTIs the most reported infection in Pakistan and KPC was prominently detected in *E. coli* (31.67%). *E. coli* indicated significant resistance for antibiotics used as first line therapy (Abdelrahim et al. 2021). Statistical analysis

indicated association between ESBL producing and non-ESBL producing UPEC isolates. Statistical significance was investigated on *E. coli* isolates obtained from UTI patients in Iran. Statistically significant difference was found for imipenem, gentamycin, levofloxacin, ciprofloxacin, Tetracycline, ampicillin and ceftazidime (Aslam et al. 2021). In Palestine, statistical analysis indicated no significance for chloramphenicol and aminoglycosides than other drugs in human clinical isolates. Both ESBL and non-ESBL *E. coli* isolates were susceptible to imipenem (Yasmin et al. 2022). Gharavi et al. did not find significant effect of ESBL expression for Imipenem, Meropenem, Nitrofurantoin, and Amikacin in *E. coli* isolates (Abrar et al. 2018). In this study, there is need to do more work on drug resistance genes of different drug groups on molecular level. There is need to explore virulence factors pertaining to UPEC in isolates recovered in this study, which can help in assessment of the virulence potential of XDR isolates and this can be added in our future projects.

Conclusion

In conclusion, the data indicated the higher prevalence of UTIs in females as compared to males. Antibiotic sensitivity analysis identified Fosfomycin and Nitrofurantoin as the most effective antimicrobials, and Cefotaxime and Amoxicillin as the least effective ones. ESBL genes were present in more than 40% UPEC and co-existed in different combinations. Some isolates also indicated the phenotypic and genotypic occurrence of carbapenem resistance genes. This situation is quite alarming, therefore, it is important to emphasize that antibiotic prescription should only be based on clinical diagnosis of urine culture. Antibiotic usage in animal husbandry should also be monitored. Routes of transmission should be identified to prevent transmission from animals to humans and vice versa. Over the counter drug availability is another main problem for generating drug resistance among pathogens. Antibiotics spread in the environment through different routs could lead to emergence of XDR and MDR pathogens. According to our knowledge, it is first study indicating the presence of KPC in UPEC as well as co-existence of different ESBL genes in UPEC from Faisalabad region.

Author contributions B.E. wrote the manuscript and prepared the figures. Y. S. and A. H. conceived the idea, improved and finalized the

Declarations

Competing interests The authors declare no competing interests.

Conflict of interest The authors declared no financial or non-financial competing interests.

Ethics approval This study was reviewed and approved by the Department Ethical Committee of GCUF. The letter is provided along with the uploaded documents (Ref. No: GCUF/BNB/2018/1177b).

Consent of participants Informed consent from patients was not required by the Ethical Committee, because there was no contact with patients and all data were de-identified.

Consent to publication No personal details of participants are included in this study, so consent to publish is not required by the participants.

References

Abdelrahim SS, Fouad M, Abdallah N, Ahmed RF, Zaki S (2021) Comparative study of CTX-M-15 producing *Escherichia coli* ST131 clone isolated from urinary tract infections and acute diarrhoea. Infect Drug Resist 14:4027–4038. https://doi.org/10.2147/IDR.S325669

Abrar S, Hussain S, Khan RA et al (2018) Prevalence of extended-spectrum-β-lactamase-producing *Enterobacteriaceae*: first systematic meta-analysis report from Pakistan. Antimicrob Resist Infect Control 7:26. https://doi.org/10.1186/s13756-018-0309-1

Adamus-Białek W, Baraniak A, Wawszczak M et al (2018) The genetic background of antibiotic resistance among clinical uropathogenic *Escherichia coli* strains. Mol Biol Rep 45(5):1055–1065. https://doi.org/10.1007/s11033-018-4254-0

Ahmed N, Khalid H, Mushtaq M et al (2022) The Molecular characterization of virulence determinants and antibiotic resistance patterns in human bacterial uropathogens. Antibiotics 11(4):516. https://doi.org/10.3390/antibiotics11040516

Akhtar SMH, Sattar A, Hayat K et al (2021) Uropathogens spectrum and antibiotic susceptibility in sexually active females of age group 20 to 40 years. RMJ 46(1):14–17

Alqasim A, Jaffal AA, Alyousef AA (2020) Prevalence and molecular characteristics of sequence type 131 clone among clinical uropathogenic *Escherichia coli* isolates in Riyadh. Saudi Arabia Saudi J Biol Sci 27(1):296–302. https://doi.org/10.1016/j.sjbs.2019.09.020

Arif A, Ullah I, Ullah O, Zaman R (2022) Identification of colistin resistance and its bactericidal activity against uropathogenic gram negative bacteria from Hayatabad Medical Complex Peshawar. Pak J Med Sci 38(4):981–986

Aruhomukama D (2020) Review of phenotypic assays for detection of extended-spectrum β-lactamases and carbapenemases: a microbiology laboratory bench guide. Afr Health Sci 20(3):1090–1108. https://doi.org/10.4314/ahs.v20i3.11

Aslam F, Lodhi H, Bashir R et al (2021) Prevalence of New Delhi Metallo-βLactamase-1 (blaNDM-1) Gene in Children from Tertiary Care Hospital of Pakistan. Pakistan J Zool 54(3):1455–1458. https://doi.org/10.17582/journal.pjz/20201021081020

Aurilio C, Sansone P, Barbarisi M et al (2022) Mechanisms of action of carbapenem resistance. Antibiotics 11(3):421. https://doi.org/10.3390/antibiotics11030421

Awan AB, Yan A, Sarwar Y et al (2021) Detection of synergistic antimicrobial resistance mechanisms in clinical isolates of *Pseudomonas aeruginosa* from post-operative wound infections. Appl Microbiol Biotechnol 105(24):9321–9332. https://doi.org/10.1007/s00253-021-11680-6

Barani A, Bafroee AST, Jabalameli L (2021) Abundance of extended-spectrum β-lactamase genes among intestinal *Escherichia coli* strains from drug users. Arch Microbiol 203(6):3245–3255. https://doi.org/10.1007/s00203-021-02316-4

Bashir S, Sarwar Y, Ali A et al (2011) Multiple drug resistance patterns in various phylogenetic groups of uropathogenic *E. coli* isolated from Faisalabad region of Pakistan. Braz J Microbiol 42(4):1278–1283. https://doi.org/10.1590/S1517-83822011000400005

Bashir S, Haque A, Sarwar Y, Ali A, Anwar M1 (2012) Virulence profile of different phylogenetic groups of locally isolated community acquired uropathogenic *E. coli* from Faisalabad region of Pakistan. Ann Clin Microbiol Antimicrob. https://doi.org/10.1186/1476-0711-11-23

Bauer AW, Kirby WMM, Sherris JC, Turck M (1996) Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 45(4):493–496. https://doi.org/10.1093/ajcp/45.4_ts.493

Baziboroun M, Bayani M, Poormontaseri Z, Shokri M, Biazar T (2018) Prevalence and antibiotic susceptibility pattern of extended spectrum beta lactamases producing *Escherichia coli* isolated from outpatients with Urinary Tract Infections in Babol, Northern of Iran. Curr Issues Pharm Med Sci 31(2):61–64. https://doi.org/10.1515/cipms-2018-0013

Bilal H, Khan MN, Rehman T et al (2021) Antibiotic resistance in Pakistan: a systematic review of past decade. BMC Infect Dis 21:244. https://doi.org/10.1186/s12879-021-05906-1

Carvalho I, Carvalho JA, Martínez-Álvarez S et al (2021) Characterization of ESBL-Producing *Escherichia coli* and *Klebsiella pneumoniae* Isolated from clinical samples in a Northern Portuguese Hospital: predominance of CTX-M-15 and high genetic diversity. Microorganisms 9(9):1914. https://doi.org/10.3390/microorganisms9091914

Chandran SP, Sarkar S, Diwan V et al (2017) Detection of virulence genes in ESBL producing, quinolone resistant commensal *Escherichia coli* from rural Indian children. J Infect Dev Ctries 11(5):387–392. https://doi.org/10.3855/jidc.8574

Choudhary S, Tomar A, Ansari K et al (2022) Antimicrobial activity of certain drugs against the different isolates found in bovine fecal samples. J Pharmacogn Phytochem 11(3):186–192

Clinical and Laboratory Standards Institute (2010) Performance standards for antimicrobial susceptibility testing twentieth informational supplement, M100–S20, vol 30. CLSI, Wayne

CLSI (2013) Performance standards for antimicrobial susceptibility testing twenty-third informational supplement. CLSI document M100–S23 Clinical and Laboratory Standards Institute, Wayne PA

CLSI (2016) Performance standards for antimicrobial susceptibility testing twenty-third informational supplement, 26th edn. CLSI document M100S Clinical and Laboratory Standards Institute, Wayne PA

Corbellini S, Scaltriti E, Piccinelli G et al (2022) Genomic characterisation of *Escherichia coli* isolates co-producing NDM-5 and OXA-1 from hospitalised patients with invasive infections. J Glob Antimicrob Resist 28:136–139. https://doi.org/10.1016/j.jgar.2021.12.018

Coura FM, Savini VMD, Xavier RGC et al (2021) Virulence genes profile and antimicrobial susceptibility of community-acquired bacterial urinary tract infections in a Brazilian hospital. Curr Microbiol 78(11):3913–3923. https://doi.org/10.1007/s00284-021-02650-2

Dagher C, Salloum T, Alousi S, Arabaghian H, Araj GF, Tokajian S (2018) Molecular characterization of Carbapenem resistant Escherichia coli recovered from a tertiary hospital in Lebanon. PLoS ONE 13(9):e0203323. https://doi.org/10.1371/journal.pone.0203323

Dhaouadi S, Soufi L, Hamza A et al (2020) Co-occurrence of mcr-1 mediated colistin resistance and β-lactamase-encoding genes in multidrug-resistant *Escherichia coli* from broiler chickens with colibacillosis in Tunisia. J Glob Antimicrob Resist 22:538–545. https://doi.org/10.1016/j.jgar.2020.03.017

Doi Y, Iovleva A, Bonomo RA (2017) The ecology of extended-spectrum β-lactamases (ESBLs) in the developed world. J Travel Med. https://doi.org/10.1093/jtm/taw102

Ebrahim-Saraie HS, Nezhad NZ, Heidari H et al (2018) Detection of antimicrobial susceptibility and integrons among extended-spectrum β-lactamase producing Uropathogenic *Escherichia coli* Isolates in Southwestern Iran. Oman Med J 33(3):218–223. https://doi.org/10.5001/omj.2018.40

Falgenhauer L, Imirzalioglu C, Oppong K et al (2019) Detection and characterization of ESBL-producing *Escherichia coli* from humans and poultry in Ghana. Front Microbiol 9:3358. https://doi.org/10.3389/fmicb.2018.03358

Farajzadeh-Sheikh A, Savari M, Hosseini Nave H et al (2020) Frequency and molecular epidemiology of class A ESBLs producing Enteroinvasive *Escherichia coli* (EIEC) isolates among patients with diarrhea. Gastroenterol Hepatol Bed Bench 13(1):77–85

Foxman B (2014) Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 28(1):1–13. https://doi.org/10.1016/j.idc.2013.09.003

Gales AC, Reis AO, Jones RN et al (2001) Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 39(1):183–190. https://doi.org/10.1128/JCM.39.1.183-190.2001

Gharavi MJ, Zarei J, Roshani-Asl P et al (2021) Comprehensive study of antimicrobial susceptibility pattern and extended spectrum beta-lactamase (ESBL) prevalence in bacteria isolated from urine samples. Sci Rep 11:578. https://doi.org/10.1038/s41598-020-79791-0021)

Godambe LP, Bandekar J, Shashidhar R et al (2017) Species specific PCR based detection of *Escherichia coli* from Indian foods. 3 Biotech 7(1):130. https://doi.org/10.1007/s13205-017-0784-8

Gundran RS, Cardenio PA, Salvador RT et al (2019) Prevalence, antibiogram, and resistance profile of extended-spectrum β-lactamase-producing *Escherichia coli* isolates from Pig Farms in Luzon. Philippines Microb Drug Resist 26(2):160–168. https://doi.org/10.1089/mdr.2019.0019

Habeeb MA, Sarwar Y, Ali A, Salman M, Haque A (2013) Rapid emergence of ESBL producers in *E. coli* causing urinary and wound infections in Pakistan. Pak J Med Sci 29(2):540–544. https://doi.org/10.12669/pjms.292.3144

Haghighatpanah M, Mojtahedi A (2019) Characterization of antibiotic resistance and virulence factors of *Escherichia coli* strains isolated from Iranian in patients with urinary tract infections. Infect Drug Resist 12:2747–2754. https://doi.org/10.2147/IDR.S219696

Hao J, Zeng Z, Xiao X et al (2022) Genomic and phenotypic characterization of a colistin-resistant *Escherichia coli* Isolate co-harboring bla_{NDM-5}, bla_{OXA-1}, and $bla_{CTX-M-55}$ isolated from urine. Infect Drug Resist 15:1329–1343. https://doi.org/10.2147/IDR.S355010

Hassuna NA, Khairalla AS, Farahat EM, Hammad AM, Abdel-Fattah M (2020) Molecular characterization of extended-spectrum β lactamase- producing *E. coli* recovered from community-acquired urinary tract infections in upper Egypt. Sci Rep 10:2772. https://doi.org/10.1038/s41598-020

Hussain HI, Aqib AI, Seleem MN et al (2021) Genetic basis of molecular mechanisms in β-lactam resistant gram-negative bacteria. Microb Pathog 158:105040. https://doi.org/10.1016/j.micpath.2021.105040

Iqbal Z, Mumtaz MZ, Malik A (2021) Extensive drug-resistance in strains of *Escherichia coli* and *Klebsiella pneumoniae* isolated from paediatric urinary tract infections. J Taibah Univ Med Sci 16(4):565–574

Jalal NA, Al-Ghamdi AM, Momenah AM et al (2023) Prevalence and antibiogram Pattern of *Klebsiella pneumoniae* in a Tertiary Care Hospital in Makkah, Saudi Arabia: An 11-Year Experience. Antibiotics 12(1):164. https://doi.org/10.3390/antibiotics12010164

Kahlmeter G, Poulsen HO (2012) Antimicrobial susceptibility of *Escherichia coli* from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited. Int J Antimicrob Agents 39(1):45–51. https://doi.org/10.1016/j.ijantimicag.2011.09.013

Khan H, Bari F (2021) Extended spectrum Beta lactamases (ESBLs): preference for age and gender; a hospital-based study. Microb Infect Dis 2(2):326–332. https://doi.org/10.21608/MID.2020.41773.1061

Kim H, Kim YA, Seo YH, Lee H, Lee K (2021) Prevalence and molecular epidemiology of extended-spectrum-β-lactamase (ESBL)-producing *Escherichia coli* from multiple sectors of poultry industry in Korea. Antibiotics 10(9):1050. https://doi.org/10.3390/antibiotics10091050

Kurittu P, Khakipoor B, Aarnio M et al (2021) *Plasmid-Borne and Chromosomal ESBL/AmpC Genes in Escherichia coli and Klebsiella pneumonia in Global Food Products*. Front Microbiol 12:592291. https://doi.org/10.3389/fmicb.2021.592291

Larramendy S, Deglaire V, Dusollier P et al (2020) Risk factors of extended-spectrum beta-lactamases-producing *escherichia coli* community acquired urinary tract infections: a systematic review. Infect Drug Resist 13:3945–3955. https://doi.org/10.2147/IDR.S269033

Legese MH, Asrat D, Aseffa A, Hasan B, Mihret A, Swedberg G (2022) Molecular epidemiology of extended-spectrum beta-lactamase and AmpC producing *Enterobacteriaceae* among sepsis patients in Ethiopia: a prospective multicenter study. Antibiotics 11(2):131. https://doi.org/10.3390/antibiotics11020131

Li P, Wang M, Li X (2017) ST37 Klebsiella pneumoniae: development of carbapenem resistance in vivo during antimicrobial therapy in neonates. Future Microbiol 12(10):891–904. https://doi.org/10.2217/fmb-2016-0165

Liu YY, Wang Y, Walsh TR et al (2016) Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16(2):161–168. https://doi.org/10.1016/S1473-3099(15)00424-7

Macareño-Castro J, Solano-Salazar A, Dong LT et al (2022) Fecal microbiota transplantation for carbapenem-Resistant *Enterobacteriaceae*: a systematic review. J Infect 84(6):749–759. https://doi.org/10.1016/j.jinf.2022.04.028

Magiorakos AP, Srinivasan A, Carey RB et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281. https://doi.org/10.1111/j.1469-0691.2011.03570.x

Mahamat OO, Lounnas M, Hide M et al (2019) High prevalence and characterization of extended-spectrum ß-lactamase producing *Enterobacteriaceae* in Chadian hospitals. BMC Infect Dis 19:205. https://doi.org/10.1186/s12879-019-3838-1

Massé J, Lardé H, Fairbrother JM et al (2021) Prevalence of antimicrobial resistance and characteristics of *Escherichia coli* isolates from fecal and manure pit samples on dairy farms in the Province of Québec. Canada. Front Vet Sci 8:654125. https://doi.org/10.3389/fvets.2021.654125

Mazumder R, Abdullah A, Ahmed D, Hussain A (2020) High prevalence of $bla_{CTX-M-15}$ Gene among extended-spectrum β-lactamase-producing *Escherichia coli* isolates causing extraintestinal infections in Bangladesh. Antibiotics 9(11):796. https://doi.org/10.3390/antibiotics9110796

Merida-Vieyra J, De Colsa-Ranero A, Calderón-Castañeda Y, Aquino-Andrade A (2020) Detection of CMY-type beta-lactamases in *Escherichia coli* isolates from paediatric patients in a in a tertiary care hospital in Mexico. Antimicrob Resist Infect Control 9:168. https://doi.org/10.1186/s13756-020-00840-4

Mir N, Khurshid R, Zafar A et al (2022) Frequency and susceptibility profile of pathogens causing urinary tract infections in pediatric population. P J M H S 16(2):142–144. https://doi.org/10.53350/pjmhs22162142

Muriuki CW, Ogonda LA, Kyanya C et al (2022) Phenotypic and genotypic characteristics of uropathogenic *Escherichia coli* Isolates from Kenya. Microb Drug Resist 28(1):31–38. https://doi.org/10.1089/mdr.2020.0432

Nader S, Alejandro H (2021) Urinary tract infections in children: epidemiology and risk factors. UpToDate, Waltham, MA, pp 1–19

Naeem S, Bilal H, Muhammad H et al (2021) Detection of blaNDM-1 gene in ESBL producing *Escherichia coli* and Klebsiella pneumoniae isolated from urine samples. J Infect Dev Ctries 15(4):516–522. https://doi.org/10.3855/jidc.12850

Nahar S, Urmi UL, Ali T et al (2022) ESBL genes, blaTEM, blaOXA, and blaSHV in poultry gut bacteria: an endemic public health burden in Bangladesh: ESBL genes in poultry gut bacteria. Bangladesh Med Res Counc Bull 47(2):165–174. https://doi.org/10.3329/bmrcb.v47i2.57775

Nasir F, M. Khan I, Kashif S, et al (2021) Prevalence of ESBLs secreting and carbapenem-resistant *E. coli* from urinary tract infection. RMJ 46(3):518–521

Nasir F, Khan MI, Kashif S et al (2021) Prevalence of ESBLs secreting and carbapenem-resistant *E. coli* from urinary tract infection. Rawal Med J 46(3):518–521

Naziri Z, Derakhshandeh A, Borchaloee AS et al (2020) Treatment failure in urinary tract infections: a warning witness for virulent multi-drug resistant esbl- producing *Escherichia coli*. Infect Drug Resist 13:1839–1850. https://doi.org/10.2147/IDR.S256131

Nosheen S, Bukhari NI, Junaid K et al (2021) Phylogenetic diversity and mutational analysis of New Delhi Metallo-β-lactamase (NDM) producing *E. coli* strains from pediatric patients in Pakistan. Saudi. J Biol Sci 28(10):5875–5883. https://doi.org/10.1016/j.sjbs.2021.06.037

Noster J, Thelen P, Hamprecht A (2021) Detection of multidrug-resistant *Enterobacterales*-from ESBLs to Carbapenemases. Antibiotics 10(9):1140. https://doi.org/10.3390/antibiotics10091140

Nwafia IN, Ohanu ME, Ebede SO, Ozumba UC (2019) Molecular detection and antibiotic resistance pattern of extended-spectrum beta-lactamase producing *Escherichia coli* in a tertiary Hospital in Enugu. Nigeria Ann Clin Microbiol Antimicrob 18:41. https://doi.org/10.1186/s12941-019-0342-9

Pandit R, Awal B, Shrestha SS, Joshi G, Rijal BP, Parajuli NP (2020) Extended-spectrum *β*-lactamase (ESBL) genotypes among multidrug-resistant uropathogenic *Escherichia coli* clinical isolates from a teaching hospital of Nepal. Interdiscip Perspect Infect Dis 2020:6525826. https://doi.org/10.1155/2020/6525826

Poirel L, Walsh TR, Cuvillier V, Nordmann P et al (2011) Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 70(1):119–123. https://doi.org/10.1016/j.diagmicrobio.2010.12.002

Rubin J, Mussio K, Xu Y et al (2020) Prevalence of antimicrobial resistance genes and integrons in commensal gram-negative bacteria in a college community. Microb Drug Resist 26(10):1227–1235. https://doi.org/10.1089/mdr.2019.0279

Sambrook J, Fritsch MT (1989) Molecular cloning. Cold Spring Harbor Laboratory Press, USA, p 2

Samin KA, Malik S, Sadiq S, Rasheeq T, Sajid NK, Iqbal W (2021) Acute Kidney injury is a risk factor among type 2 diabetic patients after UTI due to extended-spectrum beta-lactamase producing organisms. Pak J Med Health Sci 15(5):1718–1720. https://doi.org/10.53350/pjmhs211551718

Shilpakar A, Ansari M, Rai KR, Rai G, Rai SK (2021) Prevalence of multidrug-resistant and extended-spectrum beta-lactamase producing Gram-negative isolates from clinical samples in a tertiary care hospital of Nepal. Trop Med Health 49(1):23. https://doi.org/10.1186/s41182-021-00313-3

Sohail M, Khurshid M, Saleem HG et al (2015) Characteristics and antibiotic resistance of urinary tract pathogens isolated from Punjab Pakistan. Jundishapur J Microbiol 8(7):e19272. https://doi.org/10.5812/jjm.19272v2

Sun L, Xu J, He F (2018) Draft genome sequence of an NDM-5, CTX-M-15 and OXA-1 co-producing *Escherichia coli* ST167 clinical strain isolated from a urine sample. J Glob Antimicrob Resist 14:284–286. https://doi.org/10.1016/j.jgar.2018.08.005

Surgers L, Boersma P, Girard PM et al (2019) Molecular epidemiology of ESBL-producing *E. coli* and *K. pneumoniae*: establishing virulence clusters. Infect Drug Resist 12:119–127. https://doi.org/10.2147/IDR.S179134

Tandogdu Z, Wagenlehner FME (2016) Global epidemiology of urinary tract infections. Curr Opin Infect Dis 29(1):73–79. https://doi.org/10.1097/QCO.0000000000000228

Tayh G, Elmanama A, Selmi R et al (2022) Antibiotic resistance profile and molecular characterization of extraintestinal pathogenic *Escherichia coli* (ExPEC) from human clinical samples in gaza strip, palestine. Lett Appl Microbiol. https://doi.org/10.1093/lambio/ovac033

Terlizzi ME, Gribaudo G, Maffei ME (2017) UroPathogenic *Escherichia coli* (UPEC) Infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies. Front Microbiol 8:1566. https://doi.org/10.3389/fmicb.2017.01566

Tilahun M, Kassa Y, Gedefie A, Ashagire M (2021) Emerging carbapenem-resistant *Enterobacteriaceae* infection its epidemiology and novel treatment options: a review. Infect Drug Resist 14:4363–4374. https://doi.org/10.2147/IDR.S337611

Ugbo EN, Anyamene CO, Moses IB et al (2020) Prevalence of blaTEM, blaSHV, and blaCTX-M genes among extended spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* of clinical origin. Gene Rep 21:100909. https://doi.org/10.1016/j.genrep.2020.100909

Ur Rahman S, Ali T, Ali I, Khan NA, Han B, Gao J (2018) The growing functional and genetic diversity of extended spectrum beta-lactamases. Biomed Res Int 2018:9519718. https://doi.org/10.1155/2018/9519718

Wajid M, Awan AB, Saleemi MK et al (2019) Multiple Drug resistance and virulence profiling of *Salmonella enterica* serovars typhimurium and enteritidis from poultry farms of Faisalabad. Pakistan

Microb Drug Resist 25(1):133–142. https://doi.org/10.1089/mdr.2018.0121

White RT (2021) *Escherichia Coli*: placing resistance to third-generation cephalosporins and fluoroquinolones in australia and new zealand into perspective. Microbiol Aust 42:104–110. https://doi.org/10.1071/MA21031

Wu B, Qi C, Wang L et al (2020) Detection of microbial aerosols in hospital wards and molecular identification and dissemination of drug resistance of *Escherichia coli*. Environ Int 137:105479. https://doi.org/10.1016/j.envint.2020.105479

Wu D, Ding Y, Yao K, Gao W, Wang Y (2021) Antimicrobial resistance analysis of clinical *Escherichia coli* isolates in Neonatal Ward. Front Pediatr. https://doi.org/10.3389/fped.2021.670470

Yasmin S, Karim A-M, Lee S-H, Zahra R (2022) Temporal variation of meropenem resistance in *E coli* Isolated from Sewage Water in Islamabad Pakistan. Antibiotics 11(5):635. https://doi.org/10.3390/antibiotics11050635

Yengui M, Trabelsi R, Khannous L et al (2022) Rapid detection of beta-lactamases genes among *Enterobacterales* in urine samples by using real-time PCR. Biomed Res Int 2022:8612933. https://doi.org/10.1155/2022/8612933

Zeng Q, Xiao S, Gu F et al (2021) Antimicrobial resistance and molecular epidemiology of uropathogenic *Escherichia coli* isolated from female patients in Shanghai, China. Front Cell Infect Microbiol 11:653983. https://doi.org/10.3389/fcimb.2021.653983